Merck - International Biopharmaceutical Industry

news

Merck study results signal blood cancer potential for new type of immunotherapy

For years, Merck & Co. has had an upper hand over its chief cancer drug competitor Bristol Myers Squibb. In March, however, Bristol Myers beat Merck to a notable ...

30 May 2022 news blood | Bristol

Continue Reading →

news

Merck brings former executive back to lead ex-US pharmaceuticals business

Dive Brief: Merck has tapped a former executive, Joseph Romanelli, to run the company's pharmaceutical business in markets outside the U.S. after restructuring its...

25 April 2022 news Business | china

Continue Reading →

news

How Merck’s ‘puzzling’ results could impact immunotherapy’s role in early lung cancer

An immunotherapy from Merck & Co. is the latest drug of its kind to slow the return of lung cancer in clinical testing, though mixed results in the large study su...

21 March 2022 news cancer | immunotherapy

Continue Reading →

news

Merck drug for chronic cough rejected by FDA

Dive Brief: The Food and Drug Administration has rejected Merck & Co's experimental drug for chronic cough, issuing the company a complete response letter for ...

27 January 2022 news chronic | cough

Continue Reading →

news

M&A anxiety, Roche’s comeback plan and Vir’s omicron moment

The second day of the J.P. Morgan Healthcare Conference, much like the first, didn't include the type of market-moving acquisitions or announcements that might break ...

14 January 2022 news anxiety | biopharmaceutical

Continue Reading →

news

COVID-19 pills from Pfizer, Merck authorized by FDA in major pandemic milestone

Paxlovid and molnupiravir are the first oral treatments for COVID-19, potentially valuable new tools as the fast-spreading omicron variant fuels a sharp surge in case...

7 January 2022 news COVID-19 pills | FDA

Continue Reading →

news

A worrisome safety signal slows Merck’s HIV ambitions

Currently, the world's best-selling HIV medications are made up of at least three "active ingredients." But recent years have seen increasing interest in treatments t...

26 November 2021 news active ingredient | doravirine

Continue Reading →

news

FDA approves Merck’s Keytruda as first immunotherapy for early kidney cancer

Approval of Keytruda in this setting comes about six months after Merck revealed early results from a study called Keynote-564, which showed the immunotherapy could h...

19 November 2021 news clinical trial | immunotherapy

Continue Reading →

news

US pays $1B to nearly double supply of Merck’s COVID-19 pill

Merck is now in a race with Pfizer to capture the upside of COVID-19 pills, which could soon play an outsized role in the next phase of the pandemic and beyond. The ...

15 November 2021 news COVID-19 pill | Merck

Continue Reading →

news

Merck wins UK authorization to sell first COVID-19 pill

U.K. regulators have once again moved faster than the Food and Drug Administration to approve a new medicine for COVID-19. The UK's Medicines and Healthcare products ...

8 November 2021 news COVID-19 | FDA

Continue Reading →

Current Edition

Upcoming Events

Advertisement

Merck study results signal blood cancer potential for new type of immunotherapy

Merck brings former executive back to lead ex-US pharmaceuticals business

How Merck’s ‘puzzling’ results could impact immunotherapy’s role in early lung cancer

Merck drug for chronic cough rejected by FDA

M&A anxiety, Roche’s comeback plan and Vir’s omicron moment

COVID-19 pills from Pfizer, Merck authorized by FDA in major pandemic milestone

A worrisome safety signal slows Merck’s HIV ambitions

FDA approves Merck’s Keytruda as first immunotherapy for early kidney cancer

US pays $1B to nearly double supply of Merck’s COVID-19 pill

Merck wins UK authorization to sell first COVID-19 pill

International Biopharmaceutical Industry